OBJECTIVE: This study examined volatile anesthetic-mediated protection against intestinal ischemia-reperfusion injury (IRI). BACKGROUND: Intestinal IRI is a devastating complication in the perioperative period leading to systemic inflammation and multiorgan dysfunction. Volatile anesthetics, including isoflurane, have anti-inflammatory effects. We aimed to determine whether isoflurane, given after intestinal ischemia, protects against intestinal IRI and the mechanisms involved in this protection. METHODS: : After IACUC approval, mice were anesthetized with pentobarbital and subjected to 30 minutes of superior mesenteric artery ischemia, followed by 4 hours of equianesthetic doses of pentobarbital or isoflurane. Five hours after reperfusion, small intestine tissues were analyzed for morphological injury, apoptosis, neutrophil infiltration, proinflammatory mRNAs, and TGF-(Transforming Growth Factor-)β1 levels. We also assessed hepatic and renal injury after intestinal IRI. RESULTS: Intestinal IRI with pentobarbital led to significant small intestinal dysfunction with increased mucosal injury, TUNEL (transferase biotin-dUTP nick end-labeling)-positive cells, neutrophil infiltration, and proinflammatory mRNAs as well as elevated plasma alanine aminotransferase and creatinine levels. Isoflurane exposure after IRI led to significant attenuation of intestinal, hepatic, and renal injuries. Furthermore, the protective effects of isoflurane were abolished by treatment with a TGF-β1 neutralizing antibody before induction of IRI. Finally, isoflurane exposure led to increased TGF-β1 levels in intestinal epithelial cells and in plasma. CONCLUSIONS: Our findings demonstrate that isoflurane post-conditioning protects against small intestinal injury and hepatic and renal dysfunction after severe intestinal IRI via induction of intestinal epithelial TGF-β1. Our findings support therapeutic applications of volatile anesthetics during the intraoperative and postoperative periods and imply an important role of TGF-β1 signaling in modulating multiorgan injury.
OBJECTIVE: This study examined volatile anesthetic-mediated protection against intestinal ischemia-reperfusion injury (IRI). BACKGROUND: Intestinal IRI is a devastating complication in the perioperative period leading to systemic inflammation and multiorgan dysfunction. Volatile anesthetics, including isoflurane, have anti-inflammatory effects. We aimed to determine whether isoflurane, given after intestinal ischemia, protects against intestinal IRI and the mechanisms involved in this protection. METHODS: : After IACUC approval, mice were anesthetized with pentobarbital and subjected to 30 minutes of superior mesenteric artery ischemia, followed by 4 hours of equianesthetic doses of pentobarbital or isoflurane. Five hours after reperfusion, small intestine tissues were analyzed for morphological injury, apoptosis, neutrophil infiltration, proinflammatory mRNAs, and TGF-(Transforming Growth Factor-)β1 levels. We also assessed hepatic and renal injury after intestinal IRI. RESULTS: Intestinal IRI with pentobarbital led to significant small intestinal dysfunction with increased mucosal injury, TUNEL (transferase biotin-dUTP nick end-labeling)-positive cells, neutrophil infiltration, and proinflammatory mRNAs as well as elevated plasma alanine aminotransferase and creatinine levels. Isoflurane exposure after IRI led to significant attenuation of intestinal, hepatic, and renal injuries. Furthermore, the protective effects of isoflurane were abolished by treatment with a TGF-β1 neutralizing antibody before induction of IRI. Finally, isoflurane exposure led to increased TGF-β1 levels in intestinal epithelial cells and in plasma. CONCLUSIONS: Our findings demonstrate that isoflurane post-conditioning protects against small intestinal injury and hepatic and renal dysfunction after severe intestinal IRI via induction of intestinal epithelial TGF-β1. Our findings support therapeutic applications of volatile anesthetics during the intraoperative and postoperative periods and imply an important role of TGF-β1 signaling in modulating multiorgan injury.
Authors: Lin Yang; Richard M Froio; Tracey E Sciuto; Ann M Dvorak; Ronen Alon; Francis W Luscinskas Journal: Blood Date: 2005-04-05 Impact factor: 22.113
Authors: Anthony Stallion; Tzuyung D Kou; Samir Q Latifi; Kelly A Miller; Beverly B Dahms; David L Dudgeon; Alan D Levine Journal: J Pediatr Surg Date: 2005-03 Impact factor: 2.545
Authors: Alaa S Awad; Hong Ye; Liping Huang; Li Li; Frank W Foss; Timothy L Macdonald; Kevin R Lynch; Mark D Okusa Journal: Am J Physiol Renal Physiol Date: 2006-01-10
Authors: Wayne W Zhang; Mahmoud N Kulaylat; Paul M Anain; Hasan H Dosluoglu; Linda M Harris; Gregory S Cherr; Merril T Dayton; Maciej L Dryjski Journal: J Vasc Surg Date: 2004-11 Impact factor: 4.268
Authors: Jennifer Herzog-Niescery; Hans-Martin Seipp; Thomas Peter Weber; Martin Bellgardt Journal: J Clin Monit Comput Date: 2017-08-31 Impact factor: 2.502
Authors: N A Windeløv; S R Ostrowski; P I Johansson; M Wanscher; C F Larsen; A M Sørensen; L S Rasmussen Journal: Inflamm Res Date: 2015-02-20 Impact factor: 4.575
Authors: Steven S C Cho; Ina Rudloff; Philip J Berger; Michael G Irwin; Marcel F Nold; Wei Cheng; Claudia A Nold-Petry Journal: BMC Gastroenterol Date: 2013-04-22 Impact factor: 3.067
Authors: Chloé A Picq; Didier Clarençon; Valérie E Sinniger; Bruno L Bonaz; Jean-François S Mayol Journal: PLoS One Date: 2013-06-26 Impact factor: 3.240